Alternatives to amyloid for Alzheimer's disease therapies-a symposium report

• Main Authors: Cable, Jennifer (Author), Holtzman, David M. (Author), Hyman, Bradley T. (Author), Tansey, Malú Gámez (Author), Colonna, Marco (Author), Kellis, Manolis (Author), Brinton, Roberta D. (Author), Albert, Marilyn (Author), Wellington, Cheryl L. (Author), Sisodia, Sangram S. (Author), Tanzi, Rudolph E. (Author)
• Other Authors: Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory (Contributor)
• Format: Article
• Language: English
• Published: Wiley, 2021-01-08T16:31:56Z.
• Subjects: Article
• Online Access: Get fulltext

 For decades, Alzheimer's disease research has focused on amyloid as the primary pathogenic agent. This focus has driven the development of numerous amyloid-targeting therapies; however, with one possible exception, none of these therapies have been effective in preventing or delaying cognitive decline in patients, and there are no approved disease-modifying agents. It is becoming more apparent that alternative drug targets are needed to address this complex disease. An increased understanding of Alzheimer's disease pathology has highlighted the need to target the appropriate disease pathology at the appropriate time in the disease course. Preclinical and early clinical studies have focused on targets, including inflammation, tau, vascular health, and the microbiome. This report summarizes the presentations from a New York Academy of Sciences' one-day symposium entitled "Alzheimer's Disease Therapeutics: Alternatives to Amyloid," held on November 20, 2019.